BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35552308)

  • 1. The role of prostate-specific membrane antigen PET/computed tomography in the management of prostate cancer patients: could we ask for more?
    Mei R; Farolfi A; Morigi JJ; Fanti S
    Curr Opin Urol; 2022 May; 32(3):269-276. PubMed ID: 35552308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.
    Mattana F; Muraglia L; Rajwa P; Zattoni F; Marra G; Chiu PKF; Heidegger I; Kasivisvanathan V; Kesch CV; Olivier J; Preisser F; Thibault C; Valerio M; van den Bergh RCN; Gandaglia G; Ceci F;
    Eur Urol Oncol; 2023 Apr; 6(2):128-136. PubMed ID: 36804735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
    Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
    Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multicenter Prospective Clinical Trial of
    McCarthy M; Francis R; Tang C; Watts J; Campbell A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Performance of
    Esen B; Seymen H; Tarim K; Koseoglu E; Bolukbasi Y; Falay O; Selçukbiricik F; Molinas Mandel N; Kordan Y; Demirkol MO; Tilki D; Esen T
    Eur Urol Focus; 2023 Sep; 9(5):832-837. PubMed ID: 37032281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection efficacy of [
    Rosar F; Khreish F; Marlowe RJ; Schaefer-Schuler A; Burgard C; Maus S; Petto S; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2899-2909. PubMed ID: 37148297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of
    De Man K; Piron S; Van Laeken N; Delrue L; Fonteyne V; Lumen N; Van den Broeck B; Kersemans K; Ost P; Schelfhout V
    Mol Imaging Biol; 2022 Oct; 24(5):750-758. PubMed ID: 35411446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
    Afaq A; Bomanji J
    Br Med Bull; 2018 Dec; 128(1):37-48. PubMed ID: 30272121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiphasic
    Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
    J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
    Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy.
    Harsini S; Wilson D; Saprunoff H; Allan H; Gleave M; Goldenberg L; Chi KN; Kim-Sing C; Tyldesley S; Bénard F
    Cancer Imaging; 2023 Mar; 23(1):27. PubMed ID: 36932416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial.
    Joshi A; Roberts MJ; Perera M; Williams E; Rhee H; Pryor D; Lehman M; Heathcote P; Wood S; Coucher J; Gustafson S; Miles K; Vela I
    Clin Exp Metastasis; 2020 Aug; 37(4):551-560. PubMed ID: 32519046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer.
    Bukavina L; Luckenbaugh AN; Hofman MS; Hope T; Kamran SC; Murphy DG; Yamoah K; Ost P
    Eur Urol; 2023 Jun; 83(6):521-533. PubMed ID: 36404204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Body Radiation Therapy Salvage for Lymph Node Recurrent Prostate Cancer in the Era of PSMA PET Imaging.
    Hayek OE; Rais-Bahrami S; McDonald A; Galgano SJ
    Curr Urol Rep; 2023 Oct; 24(10):471-476. PubMed ID: 37395949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of FDG PET/CT in Management of Patients with Prostate Cancer.
    Sutherland DEK; Azad AA; Murphy DG; Eapen RS; Kostos L; Hofman MS
    Semin Nucl Med; 2024 Jan; 54(1):4-13. PubMed ID: 37400321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.